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Supplemental materials 
Table S1. Demographic and clinical characteristics of the study population, N=2,043 
Characteristic Category  
Total  
N=2,043 
n (%) 
Treatment outcome* 
Success 
N=1,344 
n (%) 
Failure 
N=122 
n (%) 
Death 
N=246 
n (%) 
Loss to follow up 
N=331 
n (%) 
Study Retrospective, 2000-2003 903 (44.2) 636 (47.3) 60 (49.2) 99 (40.2) 108 (32.6) 
 Prospective, 2005-2008 1140 (55.8) 708 (52.7) 62 (50.8) 147 (59.8) 223 (67.4) 
Age <45 1397 (68.4) 901 (67) 83 (68) 174 (70.7) 239 (72.2) 
 >=45 589 (28.8) 398 (29.6) 39 (32) 63 (25.6) 89 (26.9) 
 Unknown 57 (2.8) 45 (3.3) 0 (0) 9 (3.7) 3 (0.9) 
Gender Male 1367 (66.9) 884 (65.8) 88 (72.1) 155 (63) 240 (72.5) 
 Female 676 (33.1) 460 (34.2) 34 (27.9) 91 (37) 91 (27.5) 
HIV status Negative 1274 (62.4) 866 (64.4) 79 (64.8) 134 (54.5) 195 (58.9) 
 Positive 156 (7.6) 70 (5.2) 7 (5.7) 52 (21.1) 27 (8.2) 
 Unknown 613 (30) 408 (30.4) 36 (29.5) 60 (24.4) 109 (32.9) 
History of previous treatment New case 274 (13.4) 201 (15) 15 (12.3) 12 (4.9) 46 (13.9) 
 Treated with FLD 1206 (59) 787 (58.6) 69 (56.6) 146 (59.3) 204 (61.6) 
 Treated with SLD 487 (23.8) 299 (22.2) 36 (29.5) 78 (31.7) 74 (22.4) 
 Unknown 76 (3.7) 57 (4.2) 2 (1.6) 10 (4.1) 7 (2.1) 
BMI Unknown 200 (9.8) 140 (10.4) 4 (3.3) 36 (14.6) 20 (6) 
 >=18.5 1228 (60.1) 848 (63.1) 70 (57.4) 87 (35.4) 223 (67.4) 
 <18.5 615 (30.1) 356 (26.5) 48 (39.3) 123 (50) 88 (26.6) 
Cavitary disease Unknown 155 (7.6) 110 (8.2) 5 (4.1) 23 (9.3) 17 (5.1) 
 Yes 1280 (62.7) 814 (60.6) 93 (76.2) 158 (64.2) 215 (65) 
 No 608 (29.8) 420 (31.3) 24 (19.7) 65 (26.4) 99 (29.9) 
Positive baseline AFB smear Unknown 147 (7.2) 97 (7.2) 3 (2.5) 29 (11.8) 18 (5.4) 
 Yes 1517 (74.3) 963 (71.7) 96 (78.7) 185 (75.2) 273 (82.5) 
 No 379 (18.6) 284 (21.1) 23 (18.9) 32 (13) 40 (12.1) 
Baseline resistance to >=1 FQ Yes 132 (6.5) 70 (5.2) 19 (15.6) 28 (11.4) 15 (4.5) 
 No 1911 (93.5) 1274 (94.8) 103 (84.4) 218 (88.6) 316 (95.5) 
Baseline resistance to >=1 SLI Yes 412 (20.2) 242 (18.0) 44 (36.1) 70 (28.5) 56 (16.9) 
 No 1631 (79.8) 1102 (82.0) 78 (63.9) 176 (71.5) 275 (83.1) 
Time on treatment, median 
(IQR), months 
  
20.4 (16.4-24.0) 
 
21.9 (19.3-24.5) 
 
18.3 (8.5-25.6) 
 
12.4 (6.4-19.3) 
 
11.8 (6.3-17.9) 
FLD=first-line drugs. SLD=second-line drugs. BMI=body-mass index. FQ=fluoroquinolone. SLI=second-line injectable drug.  Column percents are reported. 
Treatment outcome definitions
9
: 
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Cured. An MDR-TB  patient who has completed treatment according to program protocol and has at least five consecutive negative cultures from samples collected at 
least 30 days apart in the final 12 months of treatment. If only one positive culture is reported during that time, and there is no concomitant clinical evidence of 
deterioration, a patient may still be considered cured, provided that this positive culture is followed by a minimum of three consecutive negative cultures taken at least 
30 days apart. 
Treatment completed. A patient who has completed MDR-TB treatment according to program protocol but does not meet the definition for cure because of lack of 
bacteriological results (i.e. fewer than five cultures were performed in the final 12 months of treatment). 
Treatment success. Sum of cured and treatment completed.  
Death. A patient who dies for any reason during the course of MDR-TB treatment. 
Failure. Treatment will be considered to have failed if two or more of the five cultures recorded in the final 12 months of therapy are positive, or if any one of the final 
three cultures is positive. (Treatment will also be considered to have failed if a clinical decision has been made to terminate treatment early because of poor clinical or 
radiological response or adverse events). 
Loss to follow up. A patient whose MDR-TB treatment was interrupted for two or more consecutive months for any reason without medical approval. 
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Table S2. Prognostic performance of initial sputum culture conversion in predicting treatment outcome 
(success versus failure or death), N=1,712 
Timing of 
initial SCC, 
months 
Sensitivity (95% CI)* Specificity (95% CI)* PPV based on  prevalence of successful outcome 
 
 
 
 
50%  60%  70%  80% 
≤2  27.3 (16.6-41.4) 89.8 (82.3-94.4) 72.8% 80.1% 86.2% 91.6% 
≤6  91.8 (85.9-95.4) 57.8 (42.5-71.6) 68.5% 76.5% 83.5% 89.7% 
SCC=sputum culture conversion. 
*Based on the results of bivariate generalized linear mixed model unadjusted for covariates. 
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Table S3. Multivariable analysis of association of sputum culture conversion and covariates with treatment 
outcome (success versus failure or death), incorporating the duration of the continuation phase after 6-month 
culture conversion (A) and 2-month culture conversion (B) (N=911, PETTS study only) 
 
A. 6-month SCC 
Covariates OR Lower 
Limit of 
95% CI 
Upper 
Limit of 
95% CI 
SCC 6-mo 13.09 7.51 22.83 
HIV infection    
   Positive 0.71 0.34 1.51 
   Negative  1.00   
   Unknown 0.33 0.12 0.88 
Continuation phase length, months    
   <12 0.05 0.02 0.08 
   >18 0.76 0.37 1.58 
   12-18 1.00   
Male gender 0.84 0.52 1.33 
Age 1.00 0.98 1.02 
History of previous treatment    
   Treated with first-line drugs 0.90 0.40 1.99 
   Treated with second-line drugs 0.63 0.25 1.54 
   Unknown 1.15 0.20 6.76 
   New case 1.00   
Cavitary disease    
   Yes 0.91 0.57 1.46 
   Unknown 1.25 0.24 6.56 
   No  1.00   
AFB smear status at start of treatment    
   Positive 1.52 0.72 3.18 
   Unknown 0.67 0.16 2.82 
   Negative 1.00   
Baseline resistance to ≥1 FQ 0.23 0.10 0.54 
Baseline resistance to ≥1 SLI 0.30 0.16 0.56 
Note. Bold type face indicates statistically significant results at P<0.05. aOR=adjusted odds ratio. CI=confidence interval. 
FLD=first-line drugs. SLD=second-line drugs.  FQ= fluoroquinolones. SLI=second-line injectable drug.  Adjusted odds ratios 
are estimated using multivariable random effects logistic regression. 
 
B. 2-month SCC 
Covariates OR Lower 
Limit of 
95% CI 
Upper 
Limit of 
95% CI 
SCC 2-mo:    
   HIV positive 0.50 0.12 2.11 
   HIV negative 6.64 2.57 17.17 
   HIV unknown 3.04 1.43 6.49 
Continuation phase length, months    
   <12 0.04 0.02 0.08 
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   >18 0.75 0.38 1.47 
   12-18 1.00   
Male gender 0.72 0.46 1.13 
Age 1.00 0.99 1.02 
History of previous treatment    
   Treated with first-line drugs 0.65 0.30 1.40 
   Treated with second-line drugs 0.38 0.16 0.90 
   Unknown 0.61 0.12 3.10 
   New case 1.00   
Cavitary disease    
   Yes 0.79 0.51 1.23 
   Unknown 1.23 0.26 5.85 
   No  1.00   
AFB smear status at start of treatment    
   Positive 1.50 0.75 3.01 
   Unknown 0.89 0.21 3.78 
   Negative 1.00   
Baseline resistance to ≥1 FQ 0.21 0.09 0.46 
Baseline resistance to ≥1 SLI 0.24 0.13 0.44 
Note. Bold type face indicates statistically significant results at P<0.05. aOR=adjusted odds ratio. CI=confidence interval. 
FLD=first-line drugs. SLD=second-line drugs. FQ= fluoroquinolones. SLI=second-line injectable drug.  Adjusted odds ratios 
are estimated using multivariable random effects logistic regression. 
 
 
 
